ImmuPharma (LON:IMM) Stock Price Down 10% - Here's What Happened

Key Points

• ImmuPharma's stock price fell by 10% on Monday, reaching a low of GBX 10.51 ($0.14) before closing at GBX 11.25 ($0.15), with trading volume increasing by 30% from its average.
• The company has a market capitalization of £56.23 million and reported a negative earnings per share of GBX (0.38) for the last quarter.
• ImmuPharma is a biopharmaceutical firm focused on developing peptide-based therapeutics, particularly for autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded down 10% on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). 11,107,625 shares changed hands during trading, an increase of 30% from the average session volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Price Performance

The firm has a market cap of £56.23 million, a price-to-earnings ratio of -1,264.38 and a beta of 1.53. The firm's 50 day moving average price is GBX 4.46 and its two-hundred day moving average price is GBX 3.33.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.